Related Experiment Video
Updated: Jan 29, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Insulin-like growth factor-I receptor signaling and resistance in breast cancer
Helen E Jones1, Julia Mw Gee1, Iain R Hutcheson1
1a Cardiff University, Tenovus Centre for Cancer Research, King Edward VII Avenue, Cardiff CF10 3XF, UK. joneshe1@cardiff.ac.uk.
Abstract:
Insulin-like growth factor-I receptor (IGF-IR) signaling is involved in many fundamental adverse aspects of cancer cell biology, such as proliferation, cell survival and migration. Its anti-apoptotic properties have implicated the receptor in mediating decreased sensitivity to chemotherapeutic drugs and radiation treatment; however, data are emerging that also indicates a role for IGF-IR signaling in resistance, not only to antihormones but also to antigrowth factor strategies such as agents that target the erb family of receptors. As such, IGF-IR is clearly an attractive therapeutic target for the treatment of cancer, including breast cancer, where there is evidence of clinical prominence of the IGF-IR pathway and, as such, numerous strategies are currently in development to inhibit IGF-IR signaling. This review focuses on the ability of the IGF-IR to contribute to resistance mechanisms that support breast cancer cell growth in the presence of antihormones and antigrowth factors and discusses methods to maximize antitumor effects by combination regimens cotargeting the IGF-IR that may delay, or even prevent, progression to the resistant phenotype.
Insights
Insulin-like growth factor-I receptor (IGF-IR) signaling promotes cancer growth and resistance to therapies. Inhibiting IGF-IR, especially in combination treatments, may prevent cancer progression and overcome drug resistance.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Insulin-like growth factor-I receptor (IGF-IR) signaling is crucial for cancer cell proliferation, survival, and migration.
- IGF-IR mediates resistance to chemotherapy, radiation, antihormones, and antigrowth factor therapies, including those targeting the erb family.
- The IGF-IR pathway is clinically prominent in breast cancer, making it a significant therapeutic target.
Purpose of the Study:
- To review the role of IGF-IR in mediating resistance mechanisms in breast cancer.
- To discuss combination treatment strategies targeting IGF-IR to overcome resistance.
- To explore methods for preventing or delaying the development of a resistant cancer phenotype.
Main Methods:
- Literature review focusing on IGF-IR signaling in cancer.
- Analysis of emerging data on IGF-IR's role in therapeutic resistance.
- Discussion of preclinical and clinical strategies for IGF-IR inhibition.
Main Results:
- IGF-IR signaling contributes to breast cancer cell growth despite antihormone and antigrowth factor treatments.
- IGF-IR plays a role in acquired resistance to various cancer therapies.
- Combination regimens targeting IGF-IR show potential for enhanced antitumor effects.
Conclusions:
- IGF-IR is a critical target for overcoming therapeutic resistance in breast cancer.
- Combination therapies involving IGF-IR inhibition may prevent or delay the emergence of resistant cancer phenotypes.
- Targeting IGF-IR is a promising strategy to improve treatment outcomes in breast cancer.
Related Concept Videos
Insulin: The Receptor and Signaling Pathways
Treatment Resistant Cancers
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH
Signal Sequences and Sorting Receptors
Factors Influencing Microbial Growth: Temperature

